To investigate the molecular mechanisms of breast cancer resistance progression and develop novel potential therapeutic methods for the treatment of breast cancer resistance, in the study, the role of wtap in the cell migration of breast cancer MCF-7 and adriamycin resistant MCF-7/ADR cells were determined.MTT assays showed that adriamycin inhibited the survival of MCF-7 cells more than MCF-7/ADR did. qPCR and westernblot assays showed that WTAP was highly expressed in adriamycin resistant MCF-7/ADR cells. Moreover, transwell assays showed that increasing WTAP expression in MCF-7 cells had no effect on the migration of MCF-7 cells, whereas knocking down WTAP expression in MCF-7 /ADR cells can inhibit the migration of MCF-7/ADR cells, which may be affected by inhibiting epithelialmesenchymal transition (EMT) detected by westernblot. This finding will provide a new theoretical basis and strategy for the clinical treatment of breast cancer.